美股时段
研究和试验发展
31 家 A 股上市公司 · 2026年三季报
公司数
31家
市盈率中位数
80.3倍
不含亏损公司
净利润增长
14/ 27 家
前三季度净利润同比为正
| # | 公司 | 总市值（亿元） | 市盈率 | 前三季度营收同比 | 前三季度净利润同比 |
|---|---|---|---|---|---|
| 1 | 药明康德603259 | 17.2倍 | +38.6% | +60.6% | |
| 2 | 康龙化成300759 | 45.8倍 | +19.0% | +9.3% | |
| 3 | 泰格医药300347 | 亏损 | +15.2% | −126.7% | |
| 4 | 百奥赛图688796 | 95.2倍 | +49.1% | +173.8% | |
| 5 | 昭衍新药603127 | 30.2倍 | +20.6% | +1051.9% | |
| 6 | 皓元医药688131 | 65.3倍 | +28.5% | +30.5% | |
| 7 | 成都先导688222 | 105.0倍 | +48.7% | +50.1% | |
| 8 | 百普赛斯301080 | 81.5倍 | +30.6% | +22.0% | |
| 9 | 药康生物688046 | 69.8倍 | +25.8% | +54.8% | |
| 10 | 义翘神州301047 | 75.7倍 | +18.1% | +28.4% | |
| 11 | 益诺思688710 | 169.2倍 | +37.8% | — | |
| 12 | 诺唯赞688105 | 11894.6倍 | +18.8% | +266.1% | |
| 13 | 美迪西688202 | 亏损 | +44.1% | — | |
| 14 | 药石科技300725 | 48.4倍 | +15.2% | +33.4% | |
| 15 | 近岸蛋白688137 | 亏损 | +11.5% | — | |
| 16 | 奥浦迈688293 | 238.4倍 | +172.1% | −1.1% | |
| 17 | 诺禾致源688315 | 54.4倍 | +5.7% | −14.9% | |
| 18 | 阳光诺和688621 | 1017.0倍 | −24.6% | −121.2% | |
| 19 | 毕得医药688073 | 31.2倍 | +7.4% | +36.9% | |
| 20 | 万邦医药301520 | 1566.8倍 | −12.0% | −98.3% | |
| 21 | 泓博医药301230 | 210.4倍 | +7.1% | −16.4% | |
| 22 | 阿拉丁688179 | 39.1倍 | +30.0% | +70.5% | |
| 23 | 诺思格301333 | 45.8倍 | +17.5% | −21.3% | |
| 24 | 博济医药300404 | 79.1倍 | +25.2% | +125.0% | |
| 25 | 和元生物688238 | 亏损 | +14.5% | — | |
| 26 | 睿智医药300149 | 亏损 | +16.0% | −287.9% | |
| 27 | 百诚医药301096 | 亏损 | −11.8% | −1433.3% | |
| 28 | 百花医药600721 | 165.2倍 | −22.8% | −48.5% | |
| 29 | 南模生物688265 | 319.2倍 | +21.8% | −71.1% | |
| 30 | 泰坦科技688133 | 亏损 | +5.9% | −647.2% | |
| 31 | 普蕊斯301257 | 93.7倍 | −3.7% | −91.5% |